Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). METHODS: This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only. RESULTS: The occurrences of serious adverse events were balanced across groups; none were vaccine-related. One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently in the RTS,S/AS01(E) coadministration groups. RTS,S/AS01(E) generated high anti-circumsporozoite protein and anti-hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when considering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens, predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given with RTS,S/AS01(E) at 0, 1, and 2 months. However, when antibody levels at screening were taken into account, the rates of response to polio 3 antigens were comparable between groups. CONCLUSION: RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation. Trial registration. ClinicalTrials.gov identifier: NCT00436007 . GlaxoSmithKline study ID number: 106369 (Malaria-050).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malaria: progress, perils, and prospects for eradication
Greenwood, B. M., Fidock, D. A., Kyle, D. E., Kappe, S. H. I., Alonso, P. L., Collins, F. H., & Duffy, P. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33996 · Cited by 709
Self-citationAponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Self-citationRandomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa054960 · Cited by 90
Cited by
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
RTS,S/AS01 vaccine (Mosquirix™): an overview
Laurens, M. B. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1669415 · Cited by 491
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
Neafsey, D. E., Juraska, M., Bedford, T., Benkeser, D., Valim, C., Griggs, A., Lievens, M., Abdulla, S., Adjei, S., Agbenyega, T., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505819 · Cited by 422
Self-citationWatson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 322
Coutant, F., Sanchez David, R. Y., Félix, T., Boulay, A., Caleechurn, L., Souque, P., Thouvenot, C., Bourgouin, C., Beignon, A.-S., & Charneau, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048644 · Cited by 32
“RTS,S, which is composed of a single Ag, Pf CSP, provides some protection against clinical and severe malaria [13].”
Background
Metadata
- Authors
- Agnandji, S. T., Asante, K. P., Lyimo, J., Vekemans, J., Soulanoudjingar, S. S., Owusu, R., Shomari, M., Leach, A., Fernandes, J., Dosoo, D., Chikawe, M., Issifou, S., Osei‐Kwakye, K., Lievens, M., Paricek, M., Apanga, S., Mwangoka, G., Okissi, B., Kwara, E., Minja, R., Lange, J., Boahen, O., Kayan, K., Adjei, G., Chandramohan, D., Jongert, E., Demoitié, M., Dubois, M., Carter, T., Vansadia, P., Villafana, T., Sillman, M., Savarese, B., Lapierre, D., Ballou, W. R., Greenwood, B., Tanner, M., Cohen, J., Kremsner, P. G., Lell, B., Owusu‐Agyei, S., & Abdulla, S.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10
- Volume
- 202
- Issue
- 7
- Pages
- 1076-1087
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2155513799
- Cited by
- 73
- References
- 3
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.